SEARCH

SEARCH BY CITATION

References

  • Agnelli, G., Gallus, A., Goldhaber, S.Z., Haas, S., Huisman, M.V., Hull, R.D., Kakkar, A.K., Misselwitz, F. & Schellong, S. (2007) Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation, 116, 180187.
  • Amiral, J., Bridey, F., Dreyfus, M., Vissoc, A.M., Fressinaud, E., Wolf, M. & Meyer, D. (1992) Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thrombosis and Haemostasis, 68, 9596.
  • Amiral, J., Pouplard, C., Vissac, A.M., Walenga, J.M., Jeske, W. & Gruel, Y. (2000) Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. British Journal of Haematology, 109, 336341.
  • Bartholomew, J.R., Begelman, S.M. & Almahameed, A. (2005) Heparin-induced thrombocytopenia: principles for early recognition and management. Cleveland Clinic Journal of Medicine, 72(Suppl. 1), S31S36.
  • Bradner, J., Hallisey, R.K. & Kutner, M. (2004) Fondaparinux in the treatment of heparin-induced thrombocytopenia. (abstract). Blood, 104, Abstract 1775.
  • Buller, H.R. (2006) Once-daily treatment with an oral, direct Factor Xa inhibitor - rivaroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding study (abstract). European Heart Journal, 27 (Abstract supplement), 761.
  • D’Amico, E.A., Villaca, P.R., Gualandro, S.F., Bassitt, R.P. & Chamone, D.A. (2003) Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 1, 24522453.
  • Depasse, F., Busson, J., Mnich, J., Le Flem, L., Gerotziafas, G.T. & Samama, M.M. (2005) Effect of BAY 59-7939 - a novel, oral, direct Factor Xa inhibitor - on clot-bound Factor Xa activity in vitro (abstract). Journal of Thrombosis and Haemostasis, 3, P1104.
  • Eriksson, B.I., Borris, L.C., Friedman, R.J., Haas, S., Huisman, M.V., Kakkar, A.K., Bandel, T.-J., Muehlhofer, E., Misselwitz, F. & Geerts, W. (2007) Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: the RECORD1 trial (abstract). Blood, 110, Abstract 6.
  • Franchini, M. (2005) Heparin-induced thrombocytopenia: an update. Thrombosis Journal, 3, 14.
  • Greinacher, A., Potzsch, B., Amiral, J., Dummel, V., Eichner, A. & Mueller-Eckhardt, C. (1994) Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thrombosis and Haemostasis, 71, 247251.
  • Greinacher, A., Alban, S., Dummel, V., Franz, G. & Mueller-Eckhardt, C. (1995) Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thrombosis and Haemostasis, 74, 886892.
  • Greinacher, A., Janssens, U., Berg, G., Bock, M., Kwasny, H., Kemkes-Matthes, B., Eichler, P., Volpel, H., Potzsch, B. & Luz, M. (1999a) Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation, 100, 587593.
  • Greinacher, A., Volpel, H., Janssens, U., Hach-Wunderle, V., Kemkes-Matthes, B., Eichler, P., Mueller-Velten, H.G. & Potzsch, B. (1999b) Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation, 99, 7380.
  • Greinacher, A., Lubenow, N. & Eichler, P. (2003) Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation, 108, 20622065.
  • Hursting, M.J., Lewis, B.E. & Macfarlane, D.E. (2005) Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 11, 279287.
  • Jeske, W.P. & Walenga, J.M. (2002) Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Current Opinion in Investigational Drugs, 3, 11711180.
  • Jeske, W.P., Jay, A.M., Haas, S. & Walenga, J.M. (1999) Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents. Clinical and Applied Thrombosis/Hemostasis, 5(Suppl. 1), S56S62.
  • Kakkar, A.K., Brenner, B., Dahl, O.E., Eriksson, B.I., Mouret, P., Muntz, J., Bandel, T.-J., Misselwitz, F. & Haas, S. (2007) Extended thromboprophylaxis with rivaroxaban compared with short-term thromboprophylaxis with enoxaparin after total hip arthroplasty: the RECORD2 trial (abstract). Blood, 110, Abstract 307.
  • Keeling, D., Davidson, S. & Watson, H. (2006) The management of heparin-induced thrombocytopenia. British Journal Haematology, 133, 259269.
  • Kelton, J.G. (2005) The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment. Chest, 127, 9S20S.
  • Lassen, M.R., Turpie, A.G.G., Rosencher, N., Borris, L., Ageno, W., Lieberman, J.R., Bandel, T.-J. & Misselwitz, F. (2007) Rivaroxaban – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in total knee replacement surgery: results of the RECORD3 study (abstract). Journal of Thrombosis and Haemostasis, 5, O-S-006B.
  • Lee, D.H., Warkentin, T.E., Denomme, G.A., Hayward, C.P. & Kelton, J.G. (1996) A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. British Journal of Haematology, 95, 724731.
  • Lewis, B.E., Wallis, D.E., Berkowitz, S.D., Matthai, W.H., Fareed, J., Walenga, J.M., Bartholomew, J., Sham, R., Lerner, R.G., Zeigler, Z.R., Rustagi, P.K., Jang, I.K., Rifkin, S.D., Moran, J., Hursting, M.J. & Kelton, J.G. (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation, 103, 18381843.
  • Lewis, B.E., Wallis, D.E., Leya, F., Hursting, M.J. & Kelton, J.G. (2003) Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Archives of Internal Medicine, 163, 18491856.
  • Look, K.A., Sahud, M., Flaherty, S. & Zehnder, J.L. (1997) Heparin-induced platelet aggregation vs platelet factor 4 enzyme-linked immunosorbent assay in the diagnosis of heparin-induced thrombocytopenia-thrombosis. American Journal of Clinical Pathology, 108, 7882.
  • Messmore, H., Jeske, W., Wehrmacher, W. & Walenga, J. (2003) Benefit-risk assessment of treatments for heparin-induced thrombocytopenia. Drug Safety, 26, 625641.
  • Newman, P.M. & Chong, B.H. (2000) Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood, 96, 182187.
  • Parody, R., Oliver, A., Souto, J.C. & Fontcuberta, J. (2003) Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica, 88, ECR32.
  • Perzborn, E., Strassburger, J., Wilmen, A., Pohlmann, J., Roehrig, S., Schlemmer, K.H. & Straub, A. (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. Journal of Thrombosis and Haemostasis, 3, 514521.
  • Pouplard, C., Couvret, C., Regina, S. & Gruel, Y. (2005) Development of non-pathogenic antibodies to platelet factor 4 during treatment by fondaparinux after hip surgery (abstract). Journal of Thrombosis and Haemostasis, 3, Abstract P0309.
  • Sheridan, D., Carter, C. & Kelton, J.G. (1986) A diagnostic test for heparin-induced thrombocytopenia. Blood, 67, 2730.
  • Srinivasan, A.F., Rice, L., Bartholomew, J.R., Rangaswamy, C., La Perna, L., Thompson, J.E., Murphy, S. & Baker, K.R. (2004) Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Archives of Internal Medicine, 164, 6670.
  • Suh, J.S., Aster, R.H. & Visentin, G.P. (1998) Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood, 91, 916922.
  • Tardy, B., Lecompte, T., Boelhen, F., Tardy-Poncet, B., Elalamy, I., Morange, P., Gruel, Y., Wolf, M., Francois, D., Racadot, E., Camarasa, P., Blouch, M.T., Nguyen, F., Doubine, S., Dutrillaux, F., Alhenc-Gelas, M., Martin-Toutain, I., Bauters, A., Ffrench, P., De Maistre, E., Grunebaum, L., Mouton, C., Huisse, M.G., Gouault-Heilmann, M. & Lucke, V. (2006) Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood, 108, 14921496.
  • Turpie, A.G. (2007) Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 12381247.
  • Utikal, J., Peitsch, W.K., Booken, D., Velten, F., Dempfle, C.E., Goerdt, S. & Bayerl, C. (2005) Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thrombosis and Haemostasis, 94, 895896.
  • Walenga, J.M., Jeske, W.P. & Messmore, H.L. (2000) Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. Journal of Thrombosis and Thrombolysis, 10(Suppl. 1), 1320.
  • Walenga, J.M., Jeske, W.P., Prechel, M.M. & Bakhos, M. (2004) Newer insights on the mechanism of heparin-induced thrombocytopenia. Seminars in Thrombosis and Hemostasis, 30(Suppl. 1), 5767.
  • Wallis, D.E., Workman, D.L., Lewis, B.E., Steen, L., Pifarre, R. & Moran, J.F. (1999) Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. The American Journal of Medicine, 106, 629635.
  • Warkentin, T.E. & Greinacher, A. (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126, 311S337S.
  • Warkentin, T.E. & Kelton, J.G. (1996) A 14-year study of heparin-induced thrombocytopenia. American Journal of Medicine, 101, 502507.
  • Warkentin, T.E., Cook, R.J., Marder, V.J., Sheppard, J.A., Moore, J.C., Eriksson, B.I., Greinacher, A. & Kelton, J.G. (2005) Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood, 106, 37913796.
  • Warkentin, T.E., Maurer, B.T. & Aster, R.H. (2007) Heparin-induced thrombocytopenia associated with fondaparinux. The New England Journal of Medicine, 356, 26532655.